Cowen Prime Services LLC (Private.. recently announced the acquisition of new stake in HTG Molecular Diagnostics Inc. (NASDAQ:HTGM). The institutional investor has increased its shareholding in the Healthcare company by 2.78% to 4.58 million shares with purchase of 0.12 million shares. This fresh investment now brings its stake to 6.83% valued currently at $3.04 million. In addition, The Vanguard Group, Inc. raised its holdings by 1995.0 to 1.63 million shares.

With over 1.78 million HTG Molecular Diagnostics Inc. (HTGM) shares trading Friday and a closing price of $0.37 on the day, the dollar volume was approximately $0.66 million. The shares have shown a negative weekly performance of -12.67% and its price on 08/28/20 lost nearly 0.00%. Currently, there are 65.76M common shares owned by the public and among those 49.64M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for HTGM have a consensus price objective of $1.27. The analysts have set the share’s price value over the next 12 months at a high of $2.00 and a low of $0.60 should the stock experience a downside. Incidentally, analysts’ outlook for the HTG Molecular Diagnostics Inc. stock is 2.00 for the next 12 months. But an upside of 81.5% will see the stock hit the forecast high price target while mean target price for the stock is $1.25.

Insiders at the company have transacted a total of 24 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 7,709 shares. Insider sales of the common stock occurred on 15 occasions, with total insider shares sold totaling 18,268 shares.

The top 3 mutual fund holders in HTG Molecular Diagnostics Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Putnam Capital Opportunities Fund. Vanguard Total Stock Market Index owns 0.94 million shares of the company’s stock, all valued at over $0.62 million. Putnam Capital Opportunities Fund bought 0.3 million shares to bring its total holdings to over 0.3 million shares at a value of $0.2 million. Putnam Capital Opportunities Fund now owns shares totaling to 0.45% of the shares outstanding.

Shares of HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) opened at $0.375, up $0.01 from a prior closing price of $0.37. However, the script later closed the day at $0.37, down 0.00%. The company’s stock has a 5-day price change of -12.67% and -29.55% over the past three months. HTGM shares are trading -47.29% year to date (YTD), with the 12-month market performance down to -60.98% lower. It has a 12-month low price of $0.27 and touched a high of $0.99 over the same period. Currently, 1.78 million shares have been traded, compared to an average intraday trading volume of 5.27 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -30.22%, -39.84%, and -33.74% respectively.

Institutional ownership of HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) shares accounts for 34.30% of the company’s 65.76M shares outstanding. Mutual fund holders own 21.45%, while other institutional holders and individual stakeholders account for 3.89% and 17.67% respectively.

It has a market capitalization of $26.20M and a beta (3y monthly) value of 1.28. The earnings-per-share (ttm) stands at -$0.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.76% over the week and 9.90% over the month.

Analysts forecast that HTG Molecular Diagnostics Inc. (HTGM) will achieve an EPS of -$0.08 for the current quarter, -$0.07 for the next quarter and -$0.23 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.1 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.15 a year ago. Earnings per share for the fiscal year are expected to increase by 15.30%, and 28.10% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate HTG Molecular Diagnostics Inc. (HTGM) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 1 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the HTGM, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on May 11, 2020, with the firm’s price target at. Craig Hallum coverage for the HTG Molecular Diagnostics Inc. (HTGM) stock in a research note released on March 26, 2020 offered a Hold rating with a price target of. Rodman & Renshaw was of a view on May 16, 2017 that the stock is Buy, while Rodman & Renshaw gave the stock Buy rating on August 22, 2016, issuing a price target of $5. Canaccord Genuity on their part issued Buy rating on April 04, 2016.